BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

American Society of Hematology (ASH) Annual Meeting (2021)

December 11, 2021

12.2021

American Society of Hematology (ASH) Annual Meeting (2021)

PLINABULIN RAPIDLY (WITHIN 24 HOURS) REVERSES MYELOSUPPRESSION INDUCED BY CHEMOTHERAPY

RECENT NEWS ARTICLES

  • BeyondSpring Announces Three Poster Presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting
  • BeyondSpring Files 2021 Annual Report on Form 20-F
  • BeyondSpring Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update
  • BeyondSpring to Announce Fourth Quarter and Year End 2021 Financial Results and Host a Conference Call on Thursday, April 14, 2022
  • BeyondSpring Announces Organizational Streamlining
  • BeyondSpring Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
  • BeyondSpring Pharmaceuticals Announces New Clinical Data Confirming Plinabulin’s Fast Onset Mechanism of Action in the Prevention of Chemotherapy-Induced Neutropenia at the 63rd ASH Annual Meeting and Exposition
  • BeyondSpring Pharmaceuticals Announces Analysis of New Data on the Plinabulin/Pegfilgrastim Combination in Breast Cancer at the 2021 San Antonio Breast Cancer Symposium
  • BeyondSpring Pharmaceuticals Receives Complete Response Letter from the FDA for Plinabulin New Drug Application for Prevention of Chemotherapy-Induced Neutropenia (CIN)
  • BeyondSpring Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

RECENT MEDIA COVERAGE

  • TD Ameritrade Watch List
  • Managing Chemotherapy Toxicities for Improved Patient Outcomes
  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
  • Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
  • Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
  • Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring

WORK WITH US

LifeSci Advisors
Investor Contact
Ashley R. Robinson
+1 617-430-7577
arr@lifesciadvisors.com
Media Contact
Darren Opland, Ph.D.
+1 646-627-8387
darren@lifescicomms.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

GET UPDATES

Subscribe to BeyondSpring News & Media!

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy